Provide a valuable resource to your clients or customers by linking to this resource page. Just place the following link on your website.
Mycapssa is a prescription oral somatostatin analog containing octreotide in delayed-release capsules. It is indicated for long-term maintenance treatment of acromegaly in patients who previously responded to and tolerated treatment with octreotide or lanreotide. Each capsule contains 20 mg of octreotide. Its approved use is different from the indications of injectable octreotide products.
read more about mycapssa ...Octreotide binds to somatostatin receptors and reduces the secretion of growth hormone from the pituitary gland. Lower growth hormone activity also reduces production of insulin-like growth factor 1, or IGF-1. Controlling these hormone concentrations helps manage acromegaly symptoms and biochemical disease activity.
Mycapssa is used for long-term maintenance treatment in patients with acromegaly who have shown a response to and tolerated octreotide or lanreotide. It is not intended as an automatic substitute for injectable therapy without medical assessment. IGF-1 levels, symptoms, blood glucose, and other clinical measurements are reviewed during treatment. Safety and efficacy in pediatric patients have not been established.
Mycapssa starts at 20 mg by mouth twice daily, totaling 40 mg daily. Doses can increase in 20 mg daily increments according to IGF-1 levels and symptoms, up to a maximum of 80 mg daily. Capsules are swallowed whole with water on an empty stomach, at least one hour before or two hours after eating. Patients with end-stage kidney disease start at 20 mg once daily.
Mycapssa can cause gallstones and related complications, including gallbladder inflammation or pancreatitis. Other serious concerns include high or low blood glucose, hypothyroidism, slow heart rate, cardiac conduction changes, and reduced vitamin B12 levels. Nausea, diarrhea, abdominal discomfort, and headache can occur. Blood glucose, thyroid function, IGF-1 levels, and gallbladder-related symptoms are monitored during treatment.
Mycapssa is used for maintenance treatment of acromegaly in patients who previously responded to and tolerated octreotide or lanreotide.
The recommended starting dose is 20 mg twice daily, totaling 40 mg daily.
The maximum recommended dose is 80 mg daily, typically given as 40 mg twice daily.
Yes. Capsules are taken at least one hour before a meal or at least two hours after a meal.
DailyMed - MYCAPSSA (octreotide) capsule, delayed release. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=58d80bc6-bdfb-4908-93e7-aace447c8d1a. Date Accessed October 16, 2026.
MYCAPSSA (octreotide). Chiesi USA Medical Affairs. https://chiesiusamedical.com/product/mycapssa/. Date Accessed October 16, 2026.
Octreotide. LiverTox. https://www.ncbi.nlm.nih.gov/books/NBK547947/. Date Accessed October 16, 2026.
Octreotide. MedlinePlus. https://medlineplus.gov/druginfo/meds/a620051.html. Date Accessed October 16, 2026.
Octreotide. PubChem. https://pubchem.ncbi.nlm.nih.gov/compound/octreotide. Date Accessed October 16, 2026.